Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Melanoma 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Peritoneal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × soluble LAG-3 protein, human × Clear all
NCT05747794 2024-12-17

AIPAC-003

Immutep S.A.S.

Phase 2/3 Active not recruiting
849 enrolled
Breast

Breast Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Immutep S.A.S.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡